BioCurex, Inc.(fka BOCX)

[bocxman]

Seeker: I think you are profoundly confused, and it is a shame that you sold your shares based on a complete lack of understanding of the filings. Jeez louise, that is extraordinarily lame...

First of all, Biocurex acquired the RECAF patents in exchange for ASSUMPTION of $2.3 mil in notes that Pacific owed to third parties. The note was not payable to Pacific, it was owed by Pacific!

Second of all, and most importantly, Biocurex PAID OFF THE NOTES many years ago by issuing 1.5 mil shares of common to the third party who Pacific owed the notes to. See below from the filings. Again, THE NOTES HAVE BEEN PAID OFF (by the way, unless the notes were secured against the IP, which is highly doubtful, it wouldn't matter anyways, but that's not the point).

Let's all sing this together for the poor guy that sold his position because he didn't understand it:

BIOCUREX OWNS THE RECAF PATENT.
BIOCUREX OWNS THE RECAF PATENT.
BIOCUREX OWNS THE RECAF PATENT.
BIOCUREX OWNS THE RECAF PATENT.

-------------------
On March 25, 2001, Biocurex acquired the following assets from Pacific Biosciences Research Centre, then named Curex Technologies Inc., in consideration for the assumption by Biocurex of promissory notes in the amount of $2,326,869 which were payable by Pacific Biosciences to various third parties:

Ÿ Patents

Ÿ Proprietary technology

Ÿ Cash in the amount of $129,032

Ÿ A 51% interest in Biolargo.


In May 2001, Biocurex issued 1,544,404 shares of its common stock in payment of the notes, plus accrued interest, which Biocurex assumed in connection with the acquisition of assets from Pacific Biosciences. (they issued these shares at $2 by the way)

--------------


Let me add that you clearly have ZERO faith in ABT's intelligence. ABT would never have entered into an agreement with BIOCUREX, the corporate entity, if BIOCUREX didn't hold the patents to RECAF.